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Abstract
We aimed to test if stimulation of both adenosine A2A and A2B receptors is required to produce an
effective cardioprotection against reperfusion injury. Isolated rat hearts were subjected to 30 min
regional ischemia followed by 2 h of reperfusion. The adenosine A1/A2 receptor agonist 5′-(N-
ethylcarboxamido) adenosine (NECA) given at reperfusion reduced infarct size, an effect that was
reversed by both the adenosine A2A antagonist SCH58261 and the A2B antagonist MRS1706. The
A2B agonist BAY 60-6583 but not the selective A2A agonist CGS21680 reduced infarct size.
Interestingly, a combination of BAY 60-6583 and CGS21680 further reduced infarct size. These
results suggest that both A2A and A2B receptors are involved in NECA’s anti-infarct effect at
reperfusion. NECA attenuated mitochondrial swelling upon reperfusion and this was blocked by both
SCH58261 and MRS1706, indicating that activation of A2 receptors with NECA can modulate
reperfusion-induced mitochondrial permeability transition pore (mPTP) opening. In support, NECA
also prevented oxidant-induced loss of mitochondrial membrane potential (ΔΨm) and matrix Ca2+
overload in cardiomyocytes via both the A2 receptors. In addition, NECA increased mitochondrial
glycogen synthase kinase 3β (GSK-3β) phosphorylation upon reperfusion and this was again blocked
by SCH58261 and MRS1706. In conclusion, A2A and A2B receptors work in concert to prevent
reperfusion injury in rat hearts treated with NECA. NECA may protect the heart by modulating the
mPTP opening through inactivating mitochondrial GSK-3β. A simultaneous stimulation of A2A and
A2B receptors at reperfusion is required to produce a strong cardioprotection against reperfusion
injury.
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Cardioprotection against myocardial infarction has been successfully acquired experimentally
with ischemic preconditioning and numerous chemicals. Because the protective effects of these
interventions are established when applied prior to the onset of index ischemia, it is not possible
to apply the interventions in patients with acute myocardial infarction (AMI). However, recent
studies have proposed that adenosine analogues selectively targeting A2 receptors are
promising to protect the heart at reperfusion. There are two adenosine A2 receptor subtypes
(A2A and A2B). Activation of A2A receptors at reperfusion with the selective agonist CGS21680
reduced infarct size in rabbit and dog hearts [1,2]. The protective effect of A2A activation at
reperfusion was also demonstrated in other experimental models [3-5]. Recently it has been
reported that postconditioning protects the reperfused heart by activating A2A receptors [6]. In
contrast to these reports, the effectiveness of CGS21680 at reperfusion was questioned by other
studies [7,8].
Compared to the active investigation on the role of A2A receptor in cardioprotection at
reperfusion, the role of A2B receptor had largely been unexplored until recently when Philipp
et al. reported that postconditioning protects the heart by activating A2B receptors [9]. It was
also reported that BAY 60-6583, a highly selective A2B receptor agonist, limited infarct size
in rabbit hearts when applied at reperfusion [10]. A recent study further demonstrated that the
infarct-limiting effect of PKG activator at reperfusion is attributed to activation of A2B
receptors [11]. Thus, based on these observations it is possible that both A2A and A2B receptors
are important to prevent reperfusion injury. A previous study [7] investigating the
cardioprotective effects of AMP579, a novel A1/A2 receptor agonist, on reperfusion injury
further support the importance of both A2A and A2B receptors in prevention of reperfusion
injury. In that study, the protective effect of AMP579 was blocked by the selective A2A
antagonist 8-(3-chlorostyryl)caffeine (CSC) but not by the A1 receptor antagonist 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX), implying that A2A receptors but not A1 receptors
were responsible for the action of AMP579 . Interestingly, the protective effect of AMP579 at
reperfusion mimicked by another A1/A2 receptor agonist 5′-(N-ethylcarboxamido) adenosine
(NECA) but not by the selective A2A receptor agonist CGS21680, indicating that AMP579’s
cardioprotection at reperfusion required some other drug effect or other receptor subtype
working in concert with A2A receptors. NECA has been consistently shown to protect the heart
at reperfusion [10,12,13] and Ki values of NECA for A2A and A2B receptors are 20 and 2400
nM, respectively, whereas CGS21680 has Ki values for A2A and A2B receptors of 27 and 88800
nM [14]. Obviously, NECA has a much higher affinity for A2B receptors (37-fold higher) than
CGS21680, although their Ki values for A2A are similar. Because no selective agonist for
A2B receptors was available, NECA had been the most potent A2B agonist [15] until recently
when Bayer Healthcare developed the selective A2B antagonist BAY 60-6583 [10,16]. Thus,
it is highly likely that A2A and A2B receptors work in concert to confer protection in the hearts
treated with NECA at reperfusion. Here, we would hypothesize that a simultaneous stimulation
of A2A and A2B receptors might confer a strong and consistent protection.
Materials and Methods
This study conforms to the NIH Guide for the Care and Use of Laboratory Animals (NIH
publication NO. 85-23, revised 1996).
Chemicals
NECA, SCH58261, MRS1706, CGS21680, and 8-cyclopentyl-1,3-dipropylxanthine
(DPCPX) were purchased from Tocris Bioscience (Ellisville, MO). BAY 60-6580 was
obtained from Bayer Healthcare in Germany. All antibodies were purchased from Cell
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Signaling (Beverly, CA). Fluorescence dyes were obtained from Molecular Probes (Eugene,
OR).
Perfusion of isolated rat hearts
Male Wistar rats (250-350 g) were anesthetized with thiobutabarbital sodium (100 mg/kg i.p.).
The hearts were removed rapidly and mounted on a Langendorff apparatus. The hearts were
perfused with Krebs-Henseleit buffer containing (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4,
1.8 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose, which was heated to 37°C and gassed
with 95 % O2/5 % CO2. A latex balloon connected to a pressure transducer was inserted into
the left ventricle through the left atrium. The left ventricular pressure and heart rate were
continuously recorded with a PowerLab system (ADInstruments, Mountain View, CA). A 4-0
silk suture was placed around the left coronary artery, and the ends of the suture were passed
through a small piece of soft vinyl tubing to form a snare. All hearts were allowed to stabilize
for at least 20 min. Ischemia was induced by pulling the snare and then fixing it by clamping
the tubing with a small hemostat. Total coronary artery flow was measured by timed collection
of the perfusate dripping from the heart into a graduated cylinder.
Measurement of infarct size
At the end of the experiments, the coronary artery was reoccluded, and fluorescent polymer
microspheres (2-9 μM diameter, Duke Scientific Corp) were infused to demarcate the risk zone
as the tissue without fluorescence. The hearts were weighed, frozen and cut into 1 mm slices.
The slices were incubated in 1 % triphenyltetrazolium chloride (TTC) in sodium phosphate
buffer at 37°C for 20 min. The slices were immersed in 10 % formalin to enhance the contrast
between stained (viable) and unstained (necrotic) tissue and then squeezed between glass plates
spaced exactly 1 mm apart. The myocardium at risk was identified by illuminating the slices
with U.V. light. The infarcted and risk zone regions were traced on a clear acetate sheet and
quantified with ImageTool. The areas were converted into volumes by multiplying the areas
by slice thickness. Infarct size is expressed as a percentage of the risk zone.
Isolation of adult rat cardiomyocytes
Rat cardiomyocytes were isolated enzymatically [17]. Male Wistar rats weighing 250-350 g
were anesthetized with thiobutabarbital sodium (100mg/kg, i.p.). A midline thoracotomy was
performed and the heart was removed and rapidly mounted on a Langendorff apparatus. The
heart was perfused in a non-recirculating mode with Krebs-Henseleit buffer (37°C) containing
(in mM) NaCl 118, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 1.25, and glucose
10 for 5 min to wash out blood. The buffer was bubbled with 95 % O2/5 % CO2. Then the heart
was perfused with a calcium-free buffer that contained all of the above components except
CaCl2. After 5 min of perfusion, collagenase (type II) was added to the buffer (0.1 %) and the
heart was perfused in a recirculating mode for ~15 min. The heart was removed from the
apparatus and the ventricles were placed into a beaker containing the calcium-free buffer. The
ventricles were agitated in a shaking bath (37°C) at a rate of 50 cycles/min until individual
cells were released. The released cells were suspended in an incubation buffer containing all
the components of the calcium-free buffer, 1 % bovine serum albumin, 30 mM HEPES, 60
mM taurine, 20 mM creatine, and amino acid supplements at 37°C. Calcium was gradually
added to the buffer containing the cells to a final concentration of 1.2 mM. The cells were
filtered through nylon mesh and centrifuged briefly. Finally the cells were suspended in culture
medium M199 for 4 h before experiments.
Mitochondrial isolation
Mitochondria and cytosolic fractions were isolated by differential centrifugation as previously
described [18]. Cardiac samples (or isolated cardiomyocytes) were homogenized in a buffer
Xi et al. Page 3













containing 250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM Na3VO4, 1 mM
NaF, and protease inhibitor cocktail. The homogenate was centrifuged at 1000g for 10 minutes
to remove nuclei and debris. The supernatant was centrifuged at 10000g for 30 minutes. The
resultant supernatant was subsequently centrifuged at 10000g for 1 hour to yield the cytosolic
fraction. The 10000g pellet, corresponding to the mitochondrial fraction, was resuspended and
centrifuged again at 10000g for 30 minutes. Mitochondria were then resuspended in swelling
buffer (for swelling experiments) and homogenized (for Western and immunoprecipitation).
Confocal Imaging of ΔΨm
ΔΨm was measured using confocal microscopy as reported previously [19]. Briefly, cardiac
cells cultured in a specific temperature-controlled culture dish were incubated with
tetramethylrhodamine ethyl ester (TMRE, 100 nM) in standard Tyrode solution containing
(mM) NaCl 140, KCl 6, MgCl2 1, CaCl2 1, HEPES 5, and glucose 5.8 (pH 7.4) for 10 min.
Cells were then mounted on the stage of an Olympus FV 500 laser scanning confocal
microscope. The red fluorescence was excited with a 543 nm line of argon-krypton laser line
and imaged through a 560 nm long-path filter. Temperature was maintained at 37°C with Delta
T Open Dish Systems (Bioptechs, Butler, PA). The images recorded on a computer were
quantified using Image J.
Confocal imaging of mitochondrial Ca2+
Mitochondrial Ca2+ is determined with Rhod-2. This mitochondrial Ca2+ indicator has a net
positive charge, a property that promotes its sequestration into mitochondria. Cardiomyocytes
were loaded with 2 μM Rhod-2-AM for 1 h at 4°C and then incubated for 30 min at 37°C. This
two-step cold loading/warm incubation protocol achieves exclusive loading of Rhod-2 into
mitochondria [20]. The red fluorescence was excited with a 543 nm line of argon-krypton laser
line and imaged through a 560 nm long-path filter.
Measurement of mitochondrial swelling
Intact mitochondria (0.3 mg/ml) isolated from cardiac samples taken 10 min after the onset of
reperfusion were suspended in a buffer containing (in mM) 120 KCl, 10 Tris·HCl, 5
KH2PO4, and 20 MOPS. Mitochondrial swelling was assessed spectrophotometrically as a
decrease in absorbance at 520 nm (A520) [21].
Western blotting analysis
Myocardial samples taken from risk zones were homogenized in ice-cold lysis buffer. Equal
amounts of protein were loaded and eletrophoresed on SDS-polyacrylamide gel and transferred
to a PVDF membrane. Membranes were blocked with nonfat milk, and then incubated with
the primary antibodies (1:1000) at 4 °C overnight. The primary antibody bindings were
detected with a secondary anti-rabbit antibody (1:2000) and visualized by the ECL method.
Evaluation of adenosine A2B receptor expression by quantitative RT-PCR in rat
cardiomyocytes
Total mRNA of rat cardiomyocytes was isolated using Trizol (Invitrogen) reagent. RNA was
converted to cDNA using reverse transcriptase. GADPH and A2B mRNA sequences were
identified using Rat Genome Resources of NCBI (http://www.ncbi.nlm.nih.gov). Primer pairs
for GAPDH (Forward: CAGGTTGTCTCCTGCGACTT, Reverse:
ATGTAGGCCATGAGGTCCAC) and A2B (Forward: CCAAGGACAAGCCCAAATG,
Reverse: CCGTCTGGCAGAGAACGTAT) were designed using Primer3 program. Gene
expressions were assessed by quantitative RT-PCR using QuantiTect SYBR Green PCR Kit
(Qiagen) and ABI 7900HT Fast Real-Time PCR Systems.
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All hearts were subjected to a 30 min regional ischemia followed by 2 h of reperfusion. Infusion
of NECA and inhibitors were started 5 min before the onset of reperfusion and continued for
35 min. Biopsies were collected from risk zones at 5 and 10 min after the onset of reperfusion.
Infarct size was measured 2 h after reperfusion. In the experiments measuring ΔΨm, isolated
rat cardiomyocytes were exposed to 100 μM H2O2 for 20 min. Agonists were given 10 min
before exposure to H2O2 and antagonists were applied 5 min before the application of the
agonists.
Statistical Analysis
Data are expressed as mean ± SEM and were obtained from 4 to 10 separate experiments.
Statistical significance was determined using Student t-test or one-way ANOVA followed by
Tukey’s test. A value of P < 0.05 was considered as statistically significant.
Results
NECA (100 nM) given at reperfusion significantly reduced infarct size (14.1 ± 1.9 % of risk
zone) compared to the control (37.9 ± 3.2 % of risk zone) (Fig. 1). The anti-infarct effect of
NECA was reversed by both the selective A2A antagonist SCH58261 (15 nM) and the selective
A2B antagonist MRS1706 (15 nM) (Fig. 1), indicating that both A2A and A2B receptors are
involved in the action of NECA. The selective A2A agonist CGS21680 did not reduce infarct
size (35.8 ± 3.6 % of risk zone). In contrast, the selective A2B agonist BAY 60-6580 (300 nM)
reduced infarct size to 23.8 ± 3.5 % of risk zone, although the reduction was not as great as
NECA did. Interestingly, a combination of BAY 60-6580 and CGS21680 further reduced
infarct size to 15.8 ± 1.6 % of risk zone, an effect that was equipotent with NECA, implying
that a simultaneous stimulation of A2A and A2B receptors may produce a strong protection.
To test if NECA prevents reperfusion injury by targeting the mPTP opening, we evaluated the
effect of NECA on mitochondrial swelling upon reperfusion by measuring light scattering at
A520. Compared to the control (0.266 ± 0.020), mitochondria isolated from the heart treated
with NECA had a higher value of A520 (0.530 ± 0.036), indicating that NECA may modulate
the mPTP opening at reperfusion (Fig. 2). This effect of NECA was abrogated by both
SCH58261(0.372 ± 0.021) and MRS1706 (0.319 ± 0.031) (Fig. 2), indicating that the
preventive effect of NECA on the mPTP opening is mediated by both A2A and A2B receptors.
To confirm the effect of NECA on the mPTP opening, we tested the effect of NECA on oxidant-
induced loss of ΔΨm by monitoring TMRE fluorescence with confocal microscopy in isolated
rat cardiomyocytes. As shown in Fig. 3A, 100 μM H2O2 dramatically decreased TMRE
fluorescence in control cells (38.8 ± 5.4 % of baseline), indicating that oxidant stress induces
the mPTP opening. In contrast, cells treated with NECA showed a much higher TMRE
fluorescence intensity (91.2 ± 3.7 % of baseline), implying that NECA may prevent the mPTP
opening. This action of NECA was partially but significantly inhibited by both SCH58261
(69.9 ± 4.3 % of baseline) and MRS1706 (63.2 ± 4.7 % of baseline) (Fig. 3A). To further
corroborate the inhibitory action of NECA on the mPTP opening, we then tested the effect of
NECA on oxidant induced mitochondrial Ca2+ overload by detecting Rhod-2 fluorescence with
confocal microscopy in isolated rat cardiomyocytes. Fig. 3B shows that treatment of
cardiomyocytes with 100 μM H2O2 for 20 min markedly increased Rhod-2 fluorescence
intensity (223.9 ± 23.5 of baseline), indicating that oxidant stress caused mitochondrial Ca2+
overload, which is the main cause of the mPTP opening. NECA dramatically reduced the red
fluorescence intensity to 110.0 ± 5.6 % of baseline (Fig. 3B). The action of NECA was partially
but significantly blocked by both SCH58261 (174.8 ± 18.5 % of baseline) and MRS1706 (164.7
± 9.4 % of baseline).
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To test if adenosine A2B receptors exist in cardiomyocytes, we determined A2B receptor mRNA
expression in isolated rat cardiomyocytes with RT-PCR. As shown in Fig. 4A, A2B receptor
mRNA was expressed in rat cardiomyocytes (0.7 % of GAPDH). In support, Western blotting
analysis showed that A2B receptor protein was expressed in isolated cardiomyocytes (Fig. 4B).
To determine the potential role of mitochondrial GSK-3β in the cardioprotective effect of
NECA, we measured phosphorylation levels of mitochondrial GSK-3β at Ser9. NECA
significantly enhanced mitochondrial GSK-3β phosphorylation at 5 and 10 min of reperfusion,
which was abrogated by both SCH58261 and MRS1706 (Fig. 5). We further found that the
mitochondrial total GSK-3β levels were increased upon reperfusion by the treatment with
NECA, implying that GSK-3β is translocated to mitochondria by NECA (Fig. 6).
Discussion
The present study demonstrates that both adenosine A2A and A2B receptors contribute to the
cardioprotective effect of NECA at reperfusion and that a simultaneous stimulation of the two
receptor subtypes at reperfusion may produce a strong and indubitable cardioprotection against
ischemia/reperfusion injury. Adenosine A2 receptor activation at reperfusion protects the heart
presumably by modulating the mPTP opening through inactivation of mitochondrial
GSK-3β phosphorylation.
Although preconditioning as well as many other interventions applied prior to ischemia are
well established to protect the heart from ischemia/reperfusion injury, pretreatment is seldom
possible in the clinical setting of AMI. Thus, to save myocardium in patients with AMI, it is
required that interventions must be effective when applied after ischemia has begun or at the
onset of reperfusion. In this regard, adenosine A2 receptor agonists have been frequently
demonstrated to be effective at reperfusion in various experimental settings. There are two
A2 receptor subtypes: A2A and A2B. Early studies showed that CGS21680, the selective A2A
receptor agonist, given at reperfusion protects the heart in various experimental models [1-4,
22]. Recently it has been reported that activation of A2A receptors at reperfusion with ATL146e,
another selective A2A agonist, reduced infarct size in mouse hearts [5,23]. In addition, the
cardioprotective effect of postconditioning was attenuated in A2A adenosine receptor knockout
mouse hearts, indicating that A2A receptor activation is involved in the mechanism of
postconditioning [24]. In isolated rabbit hearts, AMP579, a novel adenosine A1/A2 receptor
agonist, given at reperfusion attenuated contracture and limited infarct size, an effect that was
blocked by the selective A2A receptor antagonist CSC but not by the A1 receptor antagonist
DPCPX, indicating that A2A but not A1 receptors are involved in the action of AMP579 [7].
Interestingly, the protective effect of AMP579 was mimicked by NECA but not by the selective
A2A receptor agonist CGS21680, thus casting doubt on the effectiveness of A2A receptor
activation alone at reperfusion [7]. Similarly, Kis et al. demonstrated that the anti-infarct effect
of AMP579 given at reperfusion was abrogated by ZM241385, an A2A receptor antagonist,
but was not mimicked by CGS21680 [8]. These observations suggest that although A2A
receptor activation is crucial for prevention of reperfusion injury, stimulation of some other
receptor subtypes may also be required to produce an effective protection. Recently, it has been
reported that the selective A2B agonist BAY 60-6583 applied at reperfusion reduced infarct
size in rabbit hearts [10], indicating that A2B receptor activation leads to cardioprotection at
reperfusion. Further studies demonstrated the importance of A2B receptor activation in
cardioprotection induced by both postconditioning and PKG activation [9,11]. Thus, it seems
likely that both A2A and A2B receptors are important to protect the heart at reperfusion.
Nevertheless, little has been done to test if a simultaneous activation of A2A and A2B receptors
can lead to a strong protection at reperfusion. We assumed that A2A and A2B receptors may
work in concert to protect the heart at reperfusion.
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In the present study we tested our hypothesis with NECA. NECA has a high affinity for A2A
receptors (20 nM) and had been the most potent A2B agonist [15] until recently when the
selective A2B agonist BAY 60-6583 was available [16]. Therefore, it is highly likely that
infusion of heart with NECA at reperfusion can activate both A2A and A2B receptors. We found
that the anti-infarct effect of NECA was reversed by both the potent and selective A2A
antagonist SCH58261 (323-, 53-, and 100-fold more selective for A2A receptors than A1,
A2B, and A3 receptors, respectively) and the selective A2B antagonist MRS1706 (113-, 81-,
and 165-fold more selective for A2B receptors than A1, A2A, and A3 receptors, respectively).
However, the selective A2A agonist CGS21680 alone did not mimic the action of NECA.
Interestingly, although BAY 60-6583 (EC50 < 10 nM for human A2B receptors and > 10 μM
for A1, A2A, and A3 receptors (Table 1) [10]) could reduce infarct size, the protection was not
as great as that of NECA and the combination of CGS21680 and BAY 60-6583 further reduced
infarct size. Further experiments showed that the effects of NECA on the mPTP opening
(mitochondrial swelling, ΔΨm, and mitochondrial Ca2+) and GSK-3β phosphorylation were
also blocked by SCH58261 and MRS1706. These results clearly indicate that both A2A and
A2B receptors account for the anti-infarct effect of NECA and that simultaneous stimulation
of A2A and A2B receptors at reperfusion might confer a strong and consistent protection.
However, one may have a question: why both the receptors are needed to induce
cardioprotection? Since both of these receptors are coupled to Gs proteins and thus should have
similar downstream signals. One potential answer might be that the receptor density in
cardiomyocytes is so low that both types need to be occupied in order to launch sufficient
signals. In addition, the observation that the selective A2A agonist CGS21680 was not
protective but augmented BAY 60-6583 induced cardioprotection may suggest that A2A
receptors play a role in both transmission and enhancement of the protective signal from the
A2b receptors.
The mPTP opening is a critical determinant of myocardial ischemia/reperfusion injury [25]
and the mPTP is an important target of cardioprotection [26]. Because the mPTP opens upon
reperfusion but not during ischemia [27], interventions that modulate the pore opening may
protect the heart. It has been demonstrated that suppression of the mPTP opening by
sanglifehrin-A during first few minutes of reperfusion leads to cardioprotection against
infarction [28]. Inhibition of the mPTP opening also plays a essential role in postconditioning
[29]. Recently, our group has demonstrated that cardioprotectants such as bradykinin, IB-
MECA, and morphine applied at reperfusion protects the heart by modulating the mPTP
opening [30-32]. Thus, it is reasonable to assume that NECA may also protect the heart at
reperfusion by inhibiting the mPTP opening. In this study, NECA attenuated mitochondrial
swelling upon reperfusion in perfused rat hearts and prevented oxidant-induced ΔΨm loss and
mitochondrial Ca2+ overload in isolated rat cardiomyocytes, suggesting that NECA may
protect the heart at reperfusion by modulating the mPTP opening. Moreover, the inhibitory
action of NECA on the mPTP opening was suppressed by the antagonists of both A2A and
A2B receptors, suggesting that adenosine A2 receptor activation induced cardioprotection is
attributed to inhibition of the mitochondrial death pathway upon reperfusion. This result also
supports our view that both A2A and A2B receptors contribute to the cardioprotective effect of
NECA at reperfusion. However, in this study the preventive effects of NECA on the mPTP
opening were partially but not completely blocked by either SCH58261 or MRS1706, implying
that the mPTP is not the only target of A2 receptor activation-induced cardioprotective
signaling. Since we evaluated the effects of NECA on ΔΨm and mitochondrial matrix Ca2+
by imaging isolated adult rat cardiomyocytes with confocal microscopy, these findings also
indicate that both A2A and A2B receptors exist in rat cardiomyocytes. Previous studies have
demonstrated the presence of A2A receptors in adult rat cardiomyocytes [33,34]. In addition,
Liang et al. reported that A2B receptors exist in chick embryonic cardiac cells [35]. The current
study has also shown that the A2B receptors were detectable in isolated rat cardiomyocytes.
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Thus, these observations strongly suggest that A2 receptors in cardiomyocytes are responsible
for the cardioprotective effect of NECA.
Although the exact signaling mechanism by which various cardioprotective interventions
prevent the mPTP opening remains unclear, GSK-3β has been proposed to mediate the
convergence of cardioprotective signaling pathways to inhibit mPTP opening [36]. In support,
inactivation of GSK-3β is critical for prevention of the mPTP opening by preconditioning
[37], postconditioning [38], and bradykinin [30]. However, a recent study failed to demonstrate
that NECA given at reperfusion significantly increases GSK-3β phosphorylation at Ser9 in
isolated rabbit hearts, although there was a strong trend for increased GSK-3β phosphorylation
[13]. In this study, we found that NECA increased the phosphorylation level of GSK-3β in
mitochondria, which was reversed by both A2A and A2B receptors. A recent study by Ohori et
al. demonstrated that erythropoietin prevents oxidant-induced apoptosis in cardiomyocytes by
inactivating mitochondrial GSK-3β [39]. Thus, it is tenable to reason that activation of
adenosine A2 receptors may also share the common mechanism with erythropoietin to
modulate the mPTP opening through the inactivated form of mitochondrial GSK-3β. However,
it remains unknown if NECA-induced mitochondrial GSK-3β phosphorylation took place
within mitochondria, because our data also showed that NECA translocated GSK-3β (total) to
mitochondria, which may suggest that the increase in mitochondrial GSK-3β phosphorylation
might be due in part to the translocation of the phosphorylated form of GSK-3β from cytosol.
Although GSK-3β interactions with the mPTP components ANT (adenine nucleotide
translocator) and cyclophilin D have been proposed to be the mechanisms by which
erythropoietin [37] and resveratrol [40] modulate the mPTP opening, it remains to be
determined if NECA modulates the pore opening through the similar mechanism. Obviously,
more studies are required to define the precise mechanism by which the mitochondrial
phosphorylated form of GSK-3β suppresses the mPTP opening in the heart treated with
adenosine A2 receptor agonists.
Study limitations
We investigated the roles of adenosine A2A and A2B receptors in NECA-induced
cardioprotection against reperfusion injury applying the antagonists and agonists that target
the both receptor subtypes in perfused rat hearts or in isolated rat cardiomyocytes. Although
the antagonists and agonists used were potent and selective, use of animal lacking a specific
gene that codes an A2 receptor subtype will further help us to precisely determine the specific
A2 receptor subtype (s) that is protective when stimulated.
In conclusion, A2A and A2B receptors work in concert to prevent reperfusion injury in rat hearts
treated with NECA. NECA may protect the heart by modulating the mPTP opening through
inactivating mitochondrial GSK-3β. A simultaneous stimulation of A2A and A2B receptors at
reperfusion might be required to produce a strong and consistent cardioprotection against
reperfusion injury.
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Infarct size in isolated rat hearts. Hearts were subjected to 30 min regional ischemia followed
by 2 h of reperfusion. NECA ( n = 7) given at reperfusion reduced infarct size compared the
control (n = 6). Both the selective A2A receptor antagonist SCH58261 (SCH, n = 6) and A2B
receptor antagonist MRS1706 (MRS, n = 6) reversed the anti-infarct effect of NECA. The
selective A2A agonist CGS21680 (CGS, n = 6) failed to reduce infarct size, whereas the
selective A2B receptor antagonist BAY 60-6583 (BAY, n = 6) slightly but significantly reduced
infarct size. A combination of CGS21680 and BAY 60-6583 (n =7) further reduced infarct
size. * p < 0.05 vs. control; # p < 0.05 vs. NECA and BAY+CGS.
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Mitochondrial swelling in isolated rat hearts. Mitochondria were isolated from heart samples
collected at 10 min after the onset of reperfusion. Mitochondrial swelling was measured as a
decrease in absorbance at 520 nm (A520). NECA (n = 5) prevented mitochondrial swelling at
reperfusion, an effect that was blocked by both SCH58261 (SCH, n = 5) and MRS1706 (MRS,
n = 5). * p < 0.05 vs. control; # p < 0.05 vs. NECA.
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A, Summarized data for TMRE fluorescence intensity measured with confocal microscopy 20
min after exposure to 100 μM H2O2 in isolated rat cardiomyocytes. NECA (n =5) prevented
oxidant-induced TMRE fluorescence reduction compared to the control (n = 7) and this action
was partially but significantly inhibited by both SCH58261 (SCH, n = 5) and MRS1706 (MRS,
n = 5). * p < 0.05 vs. control; # p < 0.05 vs. NECA. B, Summarized data for Rhod-2 fluorescence
intensity measured with confocal microscopy 20 min after exposure to 100 μM H2O2 isolated
rat cardiomyocytes. NECA (n = 5) inhibited oxidant-induced increase in Rhod-2 fluorescence
compared to the control (n = 5), indicating that NECA can prevent oxidant-induced matrix
Ca2+ overload. This action of NECA was partially but significantly blocked by both SCH58261
(SCH, n = 5) and MRS1706 (MRS, n = 5). * p < 0.05 vs. control; # p < 0.05 vs. NECA.
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A, A2B receptor mRNA expression in isolated adult rat cardiomyocytes. B, Western blot
analysis of A2B receptor expression in isolated adult rat cardiomyocytes (n = 3).
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Western blot analysis of mitochondrial phospho-GSK-3β (Ser9) in cardiac samples collected
at 5 and 10 min after the onset of reperfusion. NECA (n = 6) significantly enhanced
mitochondrial GSK-3β phosphorylation, indicating that NECA can inactivate GSK-3β at
reperfusion. The effect of NECA was abrogated by both SCH58261 (SCH, n = 5) and MRS1706
(MRS, n = 5). * p < 0.05 vs. control.
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Western blot analysis of mitochondrial total GSK-3β in cardiac samples collected at 5 and 10
min after the onset of reperfusion. NECA (n = 5) increased the mitochondrial GSK-3β protein
level, indicating that NECA may translocate GSK-3β to mitochondria.
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Table 1
Binding affinity of the agonists and antagonist for adenosine receptor subtypes (Ki/Kd in nM)
A1 A2A A2B A3
Agonist
CGS21680 290 27 88800 67
NECA 14 20 2400 6.2
BAY60-6583>10000>10000 3-10 -
Antagonist
SCH58261 411.9 1.3 68.9 130
MRS1706 157 112 1.39 230
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